Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease: Effect, Safety, and Outcomes.

JACC Adv · 2025 · PMC11985053 · PMID 40132346

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

43 , 44 The weight gain observed following drug discontinuation did not achieve significance in the current study but is recognized to occur in up to two-thirds of patients following discontinuation of GLP-1 RA. 45 In this study, 61% of patients had type 2 diabetes mellitus with a mean drop in HbA1C of 0.6% treated with a mean maximal semaglutide dose of 1.3 mg and liraglutide dose of 1.8 mg, respectively.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.